Use of apixaban in adults with congenital heart disease and atrial arrhythmias: The PROTECT-AR study
Αναστάσιος Κάρτας(Aristotle University of Thessaloniki), George Giannakoulas(AHEPA University Hospital), Haralambos Karvounis(Aristotle University of Thessaloniki), Απόστολος Γαλατάς(Aristotle University of Thessaloniki), G Alexandridis(Aristotle University of Thessaloniki), Sotiria Liori(University General Hospital Attikon), Dimitrios V. Moysidis(Aristotle University of Thessaloniki), Athanasios Koutsakis(Aristotle University of Thessaloniki), Sotiria Apostolopoulou(Onassis Cardiac Surgery Center), Αndreas S. Papazoglou(Aristotle University of Thessaloniki), Diamantis Kosmidis(Aristotle University of Thessaloniki), Alexandra Frogoudaki(University General Hospital Attikon), Efstratios Karagiannidis(Aristotle University of Thessaloniki), Amalia Baroutidou(Aristotle University of Thessaloniki), Ioannis Doundoulakis(University General Hospital Attikon), Stefanos Despotopoulos(Onassis Cardiac Surgery Center), Afrodite Tzifa(Mitera Hospital), Efstathios Spiridonidis(Aristotle University of Thessaloniki), Antonios Ziakas(Aristotle University of Thessaloniki)
Cited by 10
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
European Society of Cardiology: cardiovascular disease statistics 2021
|European Heart Journal|2021|1.1k
COVID-19 in Adults With Congenital Heart Disease
|Journal of the American College of Cardiology|2021|76
Prognostic significance of diabetes mellitus in patients with atrial fibrillation
|Cardiovascular Diabetology|2021|48